Biopharma continues to rise bringing new treatment propositions in 2020

The future of pharma with growth and sound opportunities are highlighted. CPhI held events on pharma has seen the confidence in all the segments anticipating successful 2020. High quality biomanufacturing presentations were on:

·        Today’s challenge and opportunities in biomanufacturing.

·        Rethinking efficiency.

·        Effective data management to the fast delivery of therapeutics to the patients.

·        Next generation Biomanufacturing facility design and optimization.

CPhI (Comprehensive Pharmaceutical Industry) Pharma index showed the overall growth of 5.4% across the top 10 pharma nations. The key indicators pointing a strong year for pharma in 2020.

Value added medicines (VAM) in trends to subsidise addressing the unmet patients’ needs such as using existing molecule in new therapies for novel applications.

CMOs and CDMOs will rise with the expertise of understanding the cell and gene technology opportunity. However, the advanced therapies still present the fundamental challenges including, price reimbursement, immature manufacturing and regulatory requirement.

Indian Pharma forecast to grow strongly in 2020. CPhI & P-MEC India – The new analysis shows a massive improvement in India’s global reputation. A significant jump made by the country in many categories (CPhI Annual Report). The largest gains reflected in terms of ‘perceived growth potential’, ‘biologics knowledge’ making efforts to align the standards with the US and Europe and growth in Biosimilars.

India is rated as the second highest overall growth potential of any market. Companies forecast to see export of $20 billion dollars in 2020 (IBEF, Indian Brand Equity Foundation report).

Pharma industry looks increasingly towards India for high quality, low cost pharma solutions. Lots of opportunities are merging that herald for the wider industry. Women empower event is designed to celebrate influential contribution of women in the pharmaceutical industry. They help redefine and assert the leadership role women play.

The regenerative medicine and genetics in diagnosis are the key drivers. The Machine learning and artificial intelligence are expected to fuel the sector and help understand the cancer cases. Continuous introduction of biotechnological products for diagnosis, prognosis and biopharmaceutical development will lead the market. Lower cost and rise in number of services will drive the segment.

Healthcare will be disrupted by the patient driven technology, the precision medicine, to get diagnosed at the early stages and also the patient experience.

Personalized medicines and biosimilars are expected to grow and bioinformatics also witness the fastest growth including algorithm designing for efficient storage and management of genomics & proteomics data generated through studies carried out in plants, animals or human genome. Growing demand for them, is also expected to drive segment growth.

Cloud based solutions which effectively and robustly manage the parallelization and distribution of input data and user code is attributed to the growth in the bioinformatics-based methods. It also supports processing NGS generated data is a driving force in the current scenario.

Trends will transform the Biopharma are:

·        38% pharmaceutical companies expect greatest come from the big data.

·        Robotic technology and artificial intelligence are reducing the manufacturing floor time and product waste. AI can identify the slightest change in the environment and temperature before it damages the product which may cause costly shut down.

·        Due to more biologic patents expiration between 2020-2025. Biosimilar markets are expanding.

·        IQVIA predicts that value of pharmaceutical industry will increase from $1.2 trillion to $1.5 trillion by 2023.

·        For manufacturing risk managements quality international standards ISO 8573-1:2010 for compressed air must followed.

·        The pharmaceutical industry continues its investigations on marijuana-based therapies. FDA wants to make the sound decisions based on the science. However, recalls on label issues can cost $100 million or more.

·        New mobile and cloud- based solutions are enabling the rapid communication.

·        Mixing technology with improved data documenting quality, formula accuracy, and increased speed of continuous processing are able to convert the raw material into finished products with-in minutes.

·        New Technologies are not going to replace the oral dose pharmaceutical anytime.

·        Implementation of automatic processing with real-time analysis that monitors quality control of all aspects of manufacturing process.

·        Precision medicine cold be a game changer. There is a difference as pharmaceutical industry adapts to meet the demand for precision medicine for the target group as compared to traditional volume demand as one size fit for all industrial methods. FDA will be setting up guidelines to develop genetic based precision formula.

·        There is confusion on CRISPR- Cas 9 technology, so it is a legal hassle, in eukaryotic cells may be history soon. Patent Trial and Appeal Board (PTAB) declared a patent interference between 10 separate US patents applications, as of confusion that what sort of Licencing needed to commercialize this technology.

·        Gene editing adoption is accelerating as the technology finds the broader usage beyond the traditional human development. The cell therapies and gene therapies are being used in humans, are now adopted towards companion animals as well. Prime editing in a genome editing is expanded beyond CRISPR-Cas9, a new mechanism that doesn’t make double stranded DNA to break in the target sequence (except with slight modifications).

·        AI, Machine learning and quantum computing will certainly improve their ability to make potential development in future.

·        Patient driven drug development will continue to be one of the most important aspects in biopharma industry.

·        Engineered bacteria or yeast cell lines will have number of potential benefits, including the consistency of glycosylation, speed of development associated with production clone selection, higher density growth and potentially a better cost of goods. It has the ability to tightly control expressing antibodies and glycosylation can allow drug developer to finely tune the functional effects which could potentially lead to more consistent clinical performance.

Using AI, ML and quantum computing to design molecules will transform drug development, drug will come to the market at lower cost than in the past while potentially being higher in efficacy. Biopharma distribute and accelerate the product & brand in manner to get appreciated and building high trust with regulators and consumers.

https://www.cphi-online.com/worldwide-event-predicts-global-pharma-trends-for-news081081.html

https://www.genengnews.com/a-lists/8-biopharma-trends-to-watch-in-2020/

https://linchpinseo.com/trends-in-the-pharmaceutical-manufacturing-industry/

https://www.biopharmadive.com/news/biotech-trends-2020/569957/

Thank you! Please provide your feedback.